CVS Health is positioned for recovery with a 2.48% year-over-year payment increase for 2027 Medicare Advantage plans and Aetna's improved star rating. These factors, combined with prior premium re-pricing and operational efficiencies, support CVS's target margins for 2028. The company's integrated pharmacy and PBM services help reduce medical costs and improve efficiency. CVS trades at a discounted price-to-earnings ratio of 11.27x, offers a 3.3% dividend yield, and has strong upside potential, though investors are advised to wait for a price correction near support levels before buying.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
